insights_auto
Nega NTLA oshdi 7,60%?
Batafsil oʻrganishchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
12,60 US$
arrow_upward
+7,60%(+0,89) 1K
12,57 US$
arrow_downward
-0,24% (-0,030)bedtimeYopilgandan keyin
Savdolar yopilgan: 8-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNTLA tikeri uchun statistika yaratilmoqda...
Ochish
11,90 US$
Yuqori
12,64 US$
Past
11,76 US$
Bozor kapitali
1,77 mlrd
Oʻrtacha hajm
4,38 mln
Hajmi
0,00
52 haftalik eng yuqori
28,24 US$
52 haftalik eng past
7,95 US$
Aksiya boʻyicha daromad
-3,36 US$
Beta
1,80
Muomaladagi aksiyalar
140,13 mln
Xodimlar soni
377
Ochish
11,90 US$
Yuqori
12,64 US$
Past
11,76 US$
Bozor kapitali
1,77 mlrd
Oʻrtacha hajm
4,38 mln
Hajmi
0,00
52 haftalik eng yuqori
28,24 US$
52 haftalik eng past
7,95 US$
Aksiya boʻyicha daromad
-3,36 US$
Beta
1,80
Muomaladagi aksiyalar
140,13 mln
Xodimlar soni
377
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
14 soat oldin
Intellia Therapeutics (NTLA) Pullback Puts Its CRISPR Valuation Story Back In Focus
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc haqida
CEOJohn Leonard
Xodimlar soni377
Asos solingan2014
Bosh ofislarKembrij, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytintelliatx.com